Abstract

Addus HomeCare will report its quarterly results on May 4, 2026 Post Market; the preview below summarizes current forecasts on revenue, margin, earnings per share, segment trends, and the latest institutional opinions within the January 1, 2026 to April 27, 2026 window.

Market Forecast

Consensus tracking for the upcoming quarter points to revenue of 366.15 million US dollars, up 7.73% year over year, with EPS estimated at 1.55, implying 16.32% growth; the EBIT estimate is 38.95 million US dollars, up 11.22% year over year. Forecasts for gross profit margin and net profit margin have not been formally disclosed in the referenced datasets. Addus HomeCare’s operations continue to be anchored by the Personal Care segment, with Hospice and Home Health providing incremental growth vectors depending on state funding dynamics and visit productivity. The most promising near-term contribution is expected to come from Personal Care given its mix weight and volume resilience, while Hospice remains an opportunistic growth lever through case volumes and program efficiency.

Last Quarter Review

The previous quarter delivered revenue of 373.08 million US dollars, a gross profit margin of 33.13%, GAAP net profit attributable to shareholders of 29.78 million US dollars with a net profit margin of 7.98%, and adjusted EPS of 1.77, with year-over-year growth of 25.56% for revenue and 28.26% for adjusted EPS; quarter-on-quarter net profit growth was 30.35%. A key financial highlight was consistent execution against operating targets, reflected in positive EPS surprise versus estimates and sustained operating leverage. By business mix, Personal Care accounted for approximately 76.57% of revenue, Hospice 18.46%, and Home Health 4.98%; applying these shares to the quarter’s revenue implies segment revenues of about 285.55 million US dollars for Personal Care, 68.85 million US dollars for Hospice, and 18.68 million US dollars for Home Health.

Current Quarter Outlook

Main business: Personal Care

Personal Care drives the majority of company revenue and sets the tone on consolidated cash generation and operating leverage. With a consensus revenue estimate for the quarter of 366.15 million US dollars and Personal Care historically comprising about three-quarters of mix, the segment’s revenue cadence will be pivotal for both the top line and margin translation. The upcoming quarter’s EPS estimate of 1.55, up 16.32% year over year, suggests that management’s cost discipline and service-hour utilization in Personal Care remain constructive; even modest hourly-rate progress and workforce retention can create a favorable drop-through to EBIT, which is forecast to rise 11.22% year over year to 38.95 million US dollars. Mix stability will likely support gross margin resilience near recent levels, while net margin progression will depend on wage normalization and administrative expense control relative to visit volumes.

Most promising business: Hospice

Hospice, though smaller than Personal Care by mix, remains a high-visibility margin contributor through clinical intensity and census management. Within the last quarter’s revenue base, Hospice’s implied revenue of roughly 68.85 million US dollars highlights its importance to blended profitability, especially as case-mix and visit acuity can influence contribution margins. In the upcoming print, execution around referral pipelines, length of stay, and clinical staffing efficiency will be central to whether EBIT tracks the 11.22% year-over-year estimate growth implied at the consolidated level. Should operating metrics hold, Hospice can provide incremental upside to EPS against the 1.55 estimate, particularly if attrition stays contained and admission patterns hold through the end of the quarter.

Key stock-price drivers this quarter

The first determinant is revenue quality—hour growth and reimbursement alignment in Personal Care relative to labor availability and wage pressure. Markets will parse whether the 7.73% year-over-year revenue growth estimate is underpinned more by volume expansion or price/mix, as the former typically carries better scalability into EBIT. The second driver is margin durability, where the last quarter’s 33.13% gross margin and 7.98% net margin set reference points; investors will look for operating expense discipline to support EBIT’s 11.22% year-over-year growth. A third factor is execution consistency in Hospice admissions and census; steady throughput and clinical productivity can modestly lift blended margins and EPS above the 1.55 estimate if realized. Finally, capital deployment and business development remain secondary supports—organic growth carries the quarter, but any updates on pipeline, referral relationships, or cost initiatives can influence the multiple applied to forward EPS.

Analyst Opinions

Recent institutional commentary within the January 1, 2026 to April 27, 2026 period shows a split view. William Blair reiterated a Buy rating, while Barclays maintained a Sell rating with a 112.00 US dollars price target. The ratio of bullish to bearish opinions in the sampled period is evenly balanced, indicating a mixed stance overall; given the tie, the consensus tilt cannot be assigned to a single majority side. The constructive camp emphasizes the combination of steady Personal Care volumes with disciplined operating expense management that supported the last quarter’s EPS outperformance and frames the path to the current quarter’s 16.32% estimated EPS growth. This view argues that execution consistency in staffing and scheduling, together with stable reimbursement dynamics, allows the company to translate mid-single-digit to high-single-digit revenue growth into double-digit EBIT and EPS growth, as reflected by the 11.22% and 16.32% year-over-year estimates for EBIT and EPS, respectively. Proponents also note that the prior quarter’s 33.13% gross margin and 7.98% net margin provide credible baselines for incremental improvement if workforce churn and overtime trend favorably, while Hospice operating metrics can provide margin support even if overall growth normalizes. By contrast, the cautious perspective, highlighted by the Barclays Sell, points to sensitivity to wage inflation, payer trends, and potential variability in Hospice census that could cap margin expansion and compress valuation if growth or utilization softens against the 7.73% revenue growth estimate. Across both camps, the immediate debate centers on the sustainability of operating leverage after a quarter of strong execution and whether the company can meet or modestly exceed the current quarter’s 1.55 EPS estimate without relying on outsized cost actions. In sum, the prevailing institutional tone is mixed ahead of May 4, 2026, with bulls leaning on consistent execution and margin baselines and bears focused on reimbursement and labor variables that could limit upside to estimates.